Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress
Not intended for UK- and US-based media
Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain.
The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines of therapy. The confirmed overall response rate (ORR) was 48% and among the 17 patients who received only one prior line of therapy the ORR was 62%.
“The results of the BEACON CRC safety lead-in demonstrate substantial improvements in efficacy outcomes when compared to current approved standard of care benchmarks in patients with BRAF-mutant metastatic CRC. The median progression-free survival of 8 months is a meaningful improvement compared to the benchmark of about 2 months, and the overall survival of 62% at 12 months is very promising given that with current approved standards of care, half of patients will succumb to their disease within 4 to 6 months,” said Axel Grothey, M.D., Division of Hematology/Oncology, Mayo Clinic. “These data underscore the potential of this triplet combination to benefit patients with BRAF V600E -mutant metastatic CRC, who, despite their poor prognosis, currently have limited effective treatment options.”
The triple combination was generally well-tolerated with no unexpected toxicities. The most common grade 3 or 4 adverse events seen in at least 10% of patients were fatigue (13%), anemia (10%), increased blood creatine kinase (10%) and increased aspartate aminotransferase (10%).
The presentation also referenced updated, mature Phase 2 results for the doublet of encorafenib and cetuximab that showed an mOS of 9.3 months, mPFS of 4.2 months and an ORR of 24%. The data cutoff for that analysis was January 2018 with the last patient enrolled in April of 2015; a detailed presentation of these data will occur at a future medical congress.
About Colorectal Cancer
Worldwide, colorectal cancer is the third most common type of cancer in men and the second most common in women, with approximately 1.4 million new diagnoses in 2012. Globally in 2012, approximately 694,000 deaths were attributed to colorectal cancer.1 In the U.S. alone, an estimated 140,250 patients will be diagnosed with cancer of the colon or rectum in 2018, and approximately 50,000 are estimated to die of their disease.2 In the U.S., BRAF mutations are estimated to occur in 10% to 15% of patients with colorectal cancer and represent a poor prognosis for these patients.3-6 The risk of mortality in CRC patients with the BRAF V600E mutation is more than two times higher than for those with wild-type BRAF.7 Several approved standard of care benchmarks for patients with BRAF-mutant CRC whose disease has progressed after one or two prior lines of therapy, range between 4% to 8% ORR, 1.8 and 2.5 months mPFS and 4 and 6 months mOS.8–14 Recently published results (April 2018; June 2017) from BRAF-containing triplet regimens in this population resulted in an mOS of approximately 9 months. Specifically, the triplet combination of dabrafenib, a BRAF inhibitor, trametinib, a MEK inhibitor and panitumumab, a monoclonal EGFR antibody, demonstrated an mOS of 9.1 months (n=91) and the triplet combination of vemurafenib, a BRAF inhibitor, cetuximab and irinotecan, a chemotherapy, demonstrated an mOS of 9.6 months (n=49).8,15 Based on recent prospective historical data, the prevalence of microsatellite instability-high (MSI-H) in tumours from patients with metastatic BRAF-mutant CRC ranged from 14% in a recent Phase 1b/2 trial (NCT01719380) (Pierre Fabre, data on file) to 18% in a recent Southwestern Oncology Group (SWOG) randomized phase 2 trial.8
About BEACON CRC
BEACON CRC is a randomized, open-label, global trial evaluating the efficacy and safety of encorafenib, binimetinib and cetuximab in patients with BRAF-mutant metastatic CRC whose disease has progressed after one or two prior regimens. BEACON CRC is the first and only Phase 3 trial designed to test a BRAF/MEK combo targeted therapy in BRAF-mutant advanced CRC. Thirty patients were treated in the safety lead-in and received the triplet combination (encorafenib 300 mg daily, binimetinib 45 mg twice daily and cetuximab per label). Of the 30 patients, 29 had a BRAF V600E mutation. MSI-H, resulting from defective DNA mismatch repair, was detected in only 1 patient. As previously announced, the triplet combination demonstrated good tolerability, supporting initiation of the randomized portion of the trial.
The randomized portion of the BEACON CRC trial is designed to assess the efficacy of encorafenib in combination with cetuximab with or without binimetinib compared to cetuximab and irinotecan-based therapy. Approximately 615 patients are expected to be randomized 1:1:1 to receive triplet combination, doublet combination (encorafenib and cetuximab) or the control arm (irinotecan-based therapy and cetuximab). The primary endpoint of the trial is overall survival of the triplet combination compared to the control arm. Secondary endpoints address efficacy of the doublet combination compared to the control arm, and the triplet combination compared to the doublet therapy. Other secondary endpoints include PFS, ORR, duration of response, safety and tolerability. Health related quality of life data will also be assessed. The trial is being conducted at over 200 investigational sites in North America, South America, Europe and the Asia Pacific region. Patient enrollment is expected to be completed in 2018.
About Encorafenib and Binimetinib
BRAF and MEK are key protein kinases in the MAPK signaling pathway (RAS-RAF-MEK-ERK). Research has shown this pathway regulates several key cellular activities including proliferation, differentiation, survival and angiogenesis. Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, including melanoma and colorectal cancer. Encorafenib is a late-stage small molecule BRAF inhibitor and binimetinib is a late-stage small molecule MEK inhibitor, both of which target key enzymes in this pathway. Encorafenib and binimetinib are being studied in clinical trials in advanced cancer patients, including the Phase 3 BEACON CRC trial and the Phase 3 COLUMBUS trial.
The U.S. Food and Drug Administration (FDA) is currently reviewing the New Drug Applications (NDAs) to support use of the combination of encorafenib and binimetinib for the treatment of patients with BRAF V600E or BRAF V600K -mutant, unresectable or metastatic melanoma. The FDA set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 30, 2018 for both applications. The European Medicines Agency (EMA), as well as the Swiss Medicines Agency (Swissmedic) and the Australian Therapeutic Goods Administration (TGA), are reviewing the Marketing Authorization Applications (MAAs) submitted by Pierre Fabre and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted the Manufacturing and Marketing Approval (MMA) applications submitted by Ono Pharmaceutical Co, Ltd.
Encorafenib and binimetinib are investigational medicines and are not currently approved in any country.
Pierre Fabre has exclusive rights to commercialize encorafenib and binimetinib in Europe, Asia, Latin America and Australia. Pierre Fabre’s development partner, Array BioPharma, has exclusive rights in the U.S. and Canada, and has granted Ono Pharmaceutical exclusive rights to commercialize both products in Japan and South Korea. Encorafenib and binimetinib are investigational medicines and are not currently approved in any country.
 Global Cancer Facts & Figures 3rd Edition. American Cancer Society. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf. Accessed June 2018.
 Cancer Facts & Figures 2018. American Cancer Society. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed June 2018.
 Saridaki et al., PLoS One. 2013
 Loupakis et al., Br J Cancer. 2009
 Sorbye H, et al. PLoS One. 2015
 Vecchione, et al. Cell. 2016
 Safaee Ardekani G, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47054.
 Kopetz et al., ASCO 2017
 De Roock et al., Lancet Oncol, 2010
 Ulivi et al., J Transl Med. 2012
 Peeters et al., ASCO 2014
 Saridaki et al., PLoS One. 2013
 Loupakis et al., Br J Cancer. 2009
 Seymour et al., Lancet Oncol, 2013 (supplementary appendix)
 Corcoran et al., Cancer Discovery, 2018
Valérie Roucoules, (33) 1 49 10 83 84
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
IBC Grows in Scope, Reach and Diversity19.9.2018 13:03 | Tiedote
IBC2018 has closed its doors for this year and has delivered another great event with visitor figures of 55,884. As well as providing a host of new initiatives this year, the exhibition grew by 667m2 and conference delegates were up by 14% year on year. One of the most important growth figures lies in the diversity of its content with a targeted effort increasing women speakers at the conference up from 14% to 37%. The IBC International Honour for Excellence saw its first-ever woman recipient this year, too. Joan Ganz Cooney was the co-creator of the global phenomenon that is Sesame Street, 50 years ago and her trophy was collected on her behalf by one of the street’s longest residents, Ernie. The IBC App has provided real networking opportunities, with more than 91,000 interactions on the matchmaking platform. In addition, IBC trended number one on Twitter in the Netherlands on several days of the convention, with 185 million potential impressions and over 250,000 video views. Engagem
NanoSteel Launches ‘Formetrix, Inc.,’ to Commercialize Additive Manufacturing Metals19.9.2018 12:15 | Tiedote
NanoSteel®, the leader in nanostructured steel materials, today announced the spinout of its Additive Manufacturing (AM) business unit into a new corporation named, ‘Formetrix™.’ Led by an industrial leader in Additive Manufacturing and including other investors Cycad Group and SPDG, Formetrix closed its Series A capital raise to accelerate the commercialization of Formetrix’s steel alloys for 3D printing processes. Over the last four years, the team developed novel alloys with exceptional material properties that current 3D printable or metal injection molded alloys do not offer. Leveraging NanoSteel’s decade long expertise in patented steel alloy design, Formetrix’s metal powder portfolio provides an attractive combination of benefits such as higher hardness, higher ductility and higher wear resistance compared to existing alternatives. The company’s initial industry focus is on materials for hot and cold forming tool and dies (i.e. molding, casting and stamping) within the automotiv
TRIPLE-1 Has Been Successful in the 50% Curtailment Compared to the Electricity Consumption of the Conventional Mining Machine19.9.2018 11:00 | Tiedote
TRIPLE-1, Inc. (Representative director: Takuya Yamaguchi) is publicizing the numerical performance evaluation of the mining machine, “KAMIKAZE”equipped with the 7nm ASIC chip this day, 19 th September 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005227/en/ Chip (Photo: Business Wire) -- The numerical performance evaluation of the mining machine, “KAMIKAZE” equipped with the 7nm ASIC chip will be publicized. This time, in the test of the performance evaluation of the mining machine, “KAMIKAZE” equipped with the 7nm ASIC chip, we have confirmed the result as follows. • “KAMIKAZE” Performance: Energy saving performance Hashrate : 14.5 TH / s ± 5% (* at the normal state) Power Consumption : 750 W ± 5% Power Efficiency : 0.052 W / GH ± 5% • “KAMIKAZE” Official Movie https://youtu.be/Fp_K4bV639Y The mining machine, ”KAMIKAZE” equipped with the world’s most advanced 7nm ASIC chip has the same Hashrate as the main min
Alibaba Cloud and OBS Unveil Innovative Cloud Solutions for the Olympic Games19.9.2018 11:00 | Tiedote
Olympic Broadcasting Services (OBS) and Alibaba Cloud, the cloud computing arm of Alibaba Group, announced today the launch of OBS Cloud, an innovative broadcasting solution that operates entirely on the cloud, to help transform the media industry for the digital era. Set to be in place for Tokyo 2020, the OBS Cloud aims to offer all the necessary cloud components, in specialized configurations, that can support the extremely demanding content production and delivery workflows of the broadcasting of the Olympic Games. Tokyo 2020 will be a game-changer for broadcasters as it showcases new possibilities for the industry by presenting solutions on the cloud. The use of cloud technologies has been gradually adopted for content creation and distribution purposes in broadcasting, however the extremely demanding requirements for volume, speed and latency that are inherent in live sports broadcasting of major events have kept the use of the cloud at a very low level, despite its multiple advan
Alibaba Cloud to Work with Kenyan Ministry to Protect Wildlife19.9.2018 10:42 | Tiedote
Alibaba Cloud, the cloud-computing arm of Alibaba Group, and the Ministry of Tourism and Wildlife of the Republic of Kenya today agreed to explore a strategic collaboration to deploy Alibaba Cloud’s technology to support the Kenya Wildlife Protection Project. The first project under the collaboration in discussion will take place at a designated area inside the Tsavo East and West National Parks, one of Kenya’s oldest and largest protected area with over 13,500 square kilometres. Leveraging Alibaba Cloud’s powerful computing, artificial intelligence (AI) and Internet of Things (IoT) capabilities; the project will work to protect the park’s endangered elephants, rhinoceroses and lions. “It is our great honour to support the Kenyan government and make a contribution to the country’s wildlife conservation efforts. The collaboration underscores the positive impact that technology, including cloud computing, AI and IoT, can have on the planet and on wildlife protection,” said Simon Hu, Seni
GE Transportation locomotives approved for operation by Indian Railways19.9.2018 09:00 | Tiedote
GE Transportation (NYSE:GE) announced today at InnoTrans 2018 that Indian Railways has confirmed its acceptance of GE’s 4,500-horsepower diesel-electric Evolution Series prototype locomotive. This critical milestone was achieved following the successful completion of rigorous testing on Indian Railways’ tracks following the locomotive handover in February 2018. “The acceptance of these locomotives is a testament to GE’s engineering depth and understanding of the customer requirements,” said Nalin Jain, President and CEO-APAC, GE Transportation. “This is a major step towards fulfilling our contract with Indian Railways. Together we will help modernize Indian Railways' fleet, significantly upgrade India's rail infrastructure and provide critical support for India's growing economy.” A standard practice, the acceptance of the 4500hp locomotives came after months of reviewing key design aspects, documentation and a thorough validation around various parameters in the U.S. and India. The lo
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme